Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia-Reference-Cited by-同舟云学术

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

Published:2010-09-29 Issue:4 Volume:151 Page:346-353
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Agathocleous Agathoclis,Rohatiner Ama,Rule Simon,Hunter Hannah,Kerr Jonathan Paul,Neeson Susan M.,Matthews Janet,Strauss Sandra,Montoto Silvia,Johnson Peter,Radford John,Lister Andrew

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08340.x/fullpdf

Reference50 articles.

1. Proteasome inhibitors: a novel class of potent and effective antitumor agents;Adams;Cancer Research,1999

2. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma;Barr;British Journal of Haematology,2009

3. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group;Chen;Journal of Clinical Oncology,2007

4. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas;Cheson;Journal of Clinical Oncology,1999

5. The proteasome, a novel protease regulated by multiple mechanisms;De Martino;The Journal of Biological Chemistry,1999

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-01

2. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis;Blood Cancer Journal;2023-09-07

3. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience;Annals of Hematology;2022-11-14

4. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline;British Journal of Haematology;2022-01-12

5. Current approach to Waldenström Macroglobulinemia;Cancer Treatment and Research Communications;2022